510(k) Report

510(k) · Cleared

Cleared

Acon Bup One Step Buprenorphine Test Strip and Acron Bup One Step Buprenorphine Test Device

K060466510(k) TraditionalCleared Apr 21, 200658-day reviewClass II21 CFR 862.3650

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

ACON Laboratories, Inc. · DJG Enzyme Immunoassay, Opiates

Cleared on Apr 21, 2006 after a 58-day review. The FDA summary names its predicate without a number. 85 later devices descend from it.

Decided
Apr 21, 2006
Review
58 days
Class
Class II
Product code
DJG
Recalls
None
Predicates
0

85 later devices descend from it, 4 citing it directly.

Descendants, by year cleared 2010: 2 descendants cleared2006: 1 descendant cleared2012: 2 descendants cleared2014: 4 descendants cleared2016: 9 descendants cleared2013: 3 descendants cleared2015: 9 descendants cleared2011: 1 descendant cleared2018: 9 descendants cleared2020: 4 descendants cleared2023: 7 descendants cleared2019: 6 descendants cleared2017: 2 descendants cleared2025: 7 descendants cleared2021: 3 descendants cleared2024: 9 descendants cleared2022: 3 descendants cleared2026: 4 descendants cleared20052010201520202025
  1. This deviceK060466 Acon Bup One Step Buprenorphine Test Strip and Acron Bup One Step…ACON Laboratories, Inc. · 2006
  2. Descendant · cites it directly · 80 of its ownK061718 Innovacon Spectrum II Test CardInnovacon, Inc. · 2006 · Recalled
  3. Descendant · 2 generations on · 55 of its ownK122809 Advin Multi-Drug Screen Test Cassette, Dip Card and CupAdvin Biotech · 2013
  4. Descendant · 3 generations on · 16 of its ownK140748 One Step Single/Multi-Drug Test Cup, One Step Single/Multi-Drug Test…Co-Innovation Biotech Co., Ltd. · 2014
  5. Descendant · 3 generations on · 13 of its ownK182701 Wondfo T-Cup Multi-Drug Urine Test CupGuangzhou Wondfo Biotech Co., Ltd. · 2018 · Recalled
  6. Descendant · 3 generations on · 13 of its ownK142800 Rapid Single/Multi-drug Test Cup and Rapid Single/Multi-drug Test…Co-Innovation Biotech Co., Ltd. · 2014

Showing 5 of 85 descendants. See all descendants

Descendants cleared per year

2006: 12010: 22011: 12012: 22013: 32014: 42015: 92016: 92017: 22018: 92019: 62020: 42021: 32022: 32023: 72024: 92025: 72026: 4
2006high 9 (2015) · low 0 (2007)2026

Most influential descendants

Showing 5 of 85 · See all
  • K061718Innovacon Spectrum II Test CardInnovacon, Inc. · 2006 · cites it directly80descendants
  • K122809Advin Multi-Drug Screen Test Cassette, Dip Card and CupAdvin Biotech · 2013 · 2 generations on55descendants
  • K140748One Step Single/Multi-Drug Test Cup, One Step Single/Multi-Drug Test DipcardCo-Innovation Biotech Co., Ltd. · 2014 · 3 generations on16descendants
  • K182701Wondfo T-Cup Multi-Drug Urine Test CupGuangzhou Wondfo Biotech Co., Ltd. · 2018 · 3 generations on13descendants
  • K142800Rapid Single/Multi-drug Test Cup and Rapid Single/Multi-drug Test DipcardCo-Innovation Biotech Co., Ltd. · 2014 · 3 generations on13descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K060466Acon Bup One Step Buprenorphine Test Strip and Acron Bup One Step…ACON Laboratories, Inc.2006—
+1K061718Innovacon Spectrum II Test CardInnovacon, Inc.20066
+2K122809Advin Multi-Drug Screen Test Cassette, Dip Card and CupAdvin Biotech2013—
+3K140748One Step Single/Multi-Drug Test Cup, One Step Single/Multi-Drug Test DipcardCo-Innovation Biotech Co., Ltd.2014—
+3K182701Wondfo T-Cup Multi-Drug Urine Test CupGuangzhou Wondfo Biotech Co., Ltd.20181
+3K142800Rapid Single/Multi-drug Test Cup and Rapid Single/Multi-drug Test DipcardCo-Innovation Biotech Co., Ltd.2014—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
200610
201020
201110
201220
201330
201440
201590
201690
201720
201890
201960
202040
202130
202230
202370
202490
202570
202640
FIG. 1 — Lineage of K060466, 2006–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DJG? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new DJG device

  1. #1 K232659 Dochek® Multi-Drug Urine Test Cup Rx, Dochek®…score 17.6 · 8 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—FDA-cleared Buprenorphine test
Named without a submission number
—

What descends from it? (85)

See all 85

4 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K061718Innovacon Spectrum II Test CardInnovacon, Inc.200680
K113624Wondfo Buprenorphine Urine Test Wondfo Oxycodone Urine TestGuangzhou Wondfo Biotech Co., Ltd.20121
K100951Medtox Buprenorphine TestMedtox Diagnostics, Inc.20100
K093175Wondfo One Step Buprenorphine Urine Test, Oxycodone Urine Test, Propoxphene Urine Test…Guangzhou Wondfo Biotech Co., Ltd.20100

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K061718 (Innovacon, Inc., 2006) has gone furthest, with 80 descendants of its own.

How does its category compare?

All DJG devices

DJG Enzyme Immunoassay, Opiates: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · DJG

3in 2025

2007: 22008: 22009: 22010: 62011: 62012: 52013: 52014: 92015: 122016: 22017: 42018: 52019: 32020: 52021: 32022: 22023: 102024: 52025: 32026 (partial year): 3
2007high 12 (2015) · low 2 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DJG

31in 2025

2010: 187 days median2011: 233 days median2012: 95 days median2013: 60 days median2014: 62 days median2015: 141 days median2017: 101 days median2018: 134 days median2019: 235 days median2020: 30 days median2021: 422 days median2023: 140 days median2024: 150 days median2025: 31 days median2026 (partial year): 157 days median
2007high 422 (2021) · low 30 (2020)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · DJG

2in 2025

2011: 12019: 12025: 2
2007high 2 (2025) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DJG

1in 2025

2011: 42012: 12013: 42015: 32016: 22017: 12018: 12021: 22022: 12024: 32025: 1
2007high 4 (2011) · low 0 (2007)2025

MAUDE reports naming product code DJG, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20082—00
20092—00
2010618700
2011623314
201259501
201356004
201496200
20151214103
20162—02
2017410101
2018513401
2019323510
202053000
2021342202
20222—01
20231014000
2024515003
202533121
202631570—

What is it indicated for?

The ACON BUP One Step Buprenorphine Test Strip and the ACON BUP One Step Buprenorphine Test Device are rapid chromatographic immunoassays for the qualitative detection of Buprenorphine in human urine at a designated cutoff concentration of 10 ng/mL. They are intended for use by healthcare professionals including professionals at point-of-care sites to assist in the determination of drug compliance. This assay provides only a preliminary analytical test…

Read the full statement (116 words)

The ACON BUP One Step Buprenorphine Test Strip and the ACON BUP One Step Buprenorphine Test Device are rapid chromatographic immunoassays for the qualitative detection of Buprenorphine in human urine at a designated cutoff concentration of 10 ng/mL. They are intended for use by healthcare professionals including professionals at point-of-care sites to assist in the determination of drug compliance.

This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Liquid chromatography/mass spectrometry (LC/MS) are the preferred confirmatory methods.

Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K060466: Acon Bup One Step Buprenorphine Test Strip and Acron Bup One Step Buprenorphine Test Device.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K060466

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026